Get the Stockscreener App
2.16
0.00%
0.00
Biomerica Inc stock is traded at $2.16, with a volume of 1,160.
It is up +0.00% in the last 24 hours and up +5.37% over the past month.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
See More
Previous Close:
$2.16
Open:
$2.1621
24h Volume:
1,160
Relative Volume:
0.06
Market Cap:
$6.68M
Revenue:
$4.33M
Net Income/Loss:
$-4.17M
P/E Ratio:
-1.4445
EPS:
-1.4953
Net Cash Flow:
$-3.19M
1W Performance:
+0.47%
1M Performance:
+5.37%
6M Performance:
-21.74%
1Y Performance:
-40.33%
1-Day Range:
$2.1621
$2.1621
1-Week Range:
$2.11
$2.19
52-Week Range:
$1.8664
$4.60
Biomerica Inc Stock (BMRA) Company Profile
Name
Biomerica Inc
Sector
Industry
Phone
(949) 379-2875
Address
17571 VON KARMAN AVENUE, IRVINE, CA
Compare BMRA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRA
Biomerica Inc
|
2.1621 | 6.74M | 4.33M | -4.17M | -3.19M | -1.4953 |
ABT
Abbott Laboratories
|
90.68 | 163.10B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
317.19 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.44 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.35 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.36 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Biomerica Inc Stock (BMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-20 | Initiated | Colliers Securities | Buy |
| Jan-04-18 | Initiated | B. Riley FBR, Inc. | Buy |
Biomerica Inc Stock (BMRA) Latest News
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026 - Weekly Voice
An IBS diet-guided therapy gets a slot at the world's biggest GI meeting - Stock Titan
BMRA Stock Price, Quote & Chart | BIOMERICA INC (NASDAQ:BMRA) - ChartMill
BMRA (Biomerica Inc.) slips 0.91% following Q1 2026 earnings release with no available analyst consensus estimates.Hedge Fund Inspired Picks - Xã Thanh Hà
BMRA (Biomerica Inc.) posts 1.9 percent year-over-year Q1 2026 revenue dip, shares gain 4.27 percent. - Xã Vĩnh Công
Biomerica Q3 Sales Fall, Net Loss Widens Amid Restructuring - Orange County Business Journal
Biomerica (BMRA) Secures Medicare Coverage for inFoods IBS Tests - GuruFocus
Biomerica, Inc. Receives Medicare Confirmation for inFoods® IBS Claims Processing Pathway - Quiver Quantitative
Biomerica Inc Announces Medicare Administrative Contractor Confirmation of Individual Claim Review For Infoods Ibs Test - marketscreener.com
Medicare can now review claims for Biomerica's $300 IBS test - Stock Titan
Biomerica (BMRA) Stock Bonus Issue (Investor Interest) 2026-04-15Trader Community Insights - Cổng thông tin điện tử Tỉnh Sơn La
Biomerica, Inc., Phoenix Airmid Biomedical And CanAlt Health Labs Launch inFoods IBS Platform In Canada - marketscreener.com
Biomerica reports net loss of USD 1.31M in Q3 2026 - Medical Buyer
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs - The Manila Times
Up to 5 million Canadians have IBS; Biomerica brings inFoods north - Stock Titan
Biomerica's Q3 revenue falls, net loss widens on lower manufacturing sales - TradingView
Biomerica Reports Third Quarter Fiscal 2026 Financial Results - Weekly Voice
Biomerica Reports Third Quarter Fiscal 2026 Financial Results, Highlights Real-World Efficacy of inFoods® IBS and Growth in European Revenue - Quiver Quantitative
BRIEF-Biomerica Q3 Net Income USD -1.31 Million - TradingView
Press Release: Biomerica Reports Third Quarter Fiscal 2026 Financial Results - Moomoo
Biomerica 10-Q: Revenue $0.99M, EPS $(0.44) for Q3 ended Feb 28, 2026 - TradingView
Biomerica (BMRA) revenue falls 22% as losses persist and going concern risk disclosed - Stock Titan
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2026 - marketscreener.com
Update Report: Will Biomerica Inc stock benefit from M A2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Aug Breakouts: Is Biomerica Inc a strong candidate for buy and holdMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Press Releases about Biomerica, Inc.Common Stock (Nasdaq:BMRA) - FinancialContent
How does Biomerica (BMRA) Stock compare to competitors | Price at $2.16, Up 0.47%Institutional Flow - Cổng thông tin điện tử Tỉnh Sơn La
Biomerica (BMRA) to Post Earnings on Monday - Defense World
BMRA: BiomericaInteractive Chart - Zacks Investment Research
Is Biomerica (BMRA) Stock Moving Sideways | Price at $2.17, Down 0.91%Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Should value investors consider Biomerica Inc2026 Price Targets & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
AI Stocks: Whats the fair value of Biomerica Inc stockMarket Risk Report & Fast Gain Swing Alerts - baoquankhu1.vn
Rate Hike: What is the PEG ratio of Biomerica Inc2026 EndofYear Setup & Stock Portfolio Risk Management - baoquankhu1.vn
BMRA PE Ratio & Valuation, Is BMRA Overvalued - intellectia.ai
Biomerica gets first commercial order for H pylori test - MSN
Biomerica Receives First Commercial Order for its H. pylori test from one of the Largest Clinical Laboratory Chains in Europe - marketscreener.com
Biomerica (BMRA) Secures First European Order for H. pylori Test - GuruFocus
First European commercial order landed: US diagnostic product company Biomerica announces that its Helicobacter pylori detection product HP Detect™ has received the first commercial order from one of Europe's largest clinical laboratory chains. - Bitget
Biomerica Secures First Commercial Order for Hp Detect™ from Major European Laboratory Chain - Quiver Quantitative
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect) from One of the Largest Clinical Laboratory Chains in Europe - Bitget
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe - marketscreener.com
Stomach cancer bacteria drives major lab’s first order of Hp Detect test - Stock Titan
Earnings Miss: Is Biomerica Inc stock a value trap2025 Top Decliners & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Biomerica receives UK regulatory approval for H. pylori test - Investing.com
Biomerica receives UK regulatory approval for H. pylori test By Investing.com - Investing.com Nigeria
Biomerica (BMRA) Expands Market with UK Approval for hp+detect T - GuruFocus
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain - The Manila Times
Portfolio Recap: How does PSHG score in quality rankingsJuly 2025 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Market Review: Can Biomerica Inc stock double in the next yearLayoff News & Weekly High Conviction Ideas - baoquankhu1.vn
Biomerica reports real-world IBS test results, Medicare rate set - Investing.com
Biometrica Down on Study - Baystreet.ca
Biomerica Inc Stock (BMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):